<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431247</url>
  </required_header>
  <id_info>
    <org_study_id>CR107277</org_study_id>
    <secondary_id>TMC114FD2HTX3001</secondary_id>
    <secondary_id>2015-000754-38</secondary_id>
    <nct_id>NCT02431247</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects</brief_title>
  <official_title>A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority in efficacy of a
      darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination
      (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC coadministered with
      Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC in human immunodeficiency virus-1
      (HIV-1) infected, antiretroviral (ARV) treatment naive adult participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter (when more than one hospital or medical school team work on a
      medical research study), randomized (study drug assigned by chance), double-blind (a medical
      research study in which neither the researchers nor the participant know what treatment the
      participant is receiving), active-controlled (study in which the experimental treatment or
      procedure is compared to a standard [control] treatment or procedure) study. The study
      consists of 5 periods: a Screening period, Double-blind treatment period, Single-arm
      treatment period, Extension period and a Follow-up period. Participants will receive either
      darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) fixed
      dose combination (D/C/F/TAF FDC) or DRV/COBI FDC along with FTC/TDF FDC. Primarily percentage
      of participants with human immunodeficiency virus (HIV) -1 Ribonucleic acid (RNA) less than
      (&lt;) 50 copies per milliliter (copies/ml) defined by snapshot analysis will be evaluated.
      Participants' safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (&lt;) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach</measure>
    <time_frame>At Week 48</time_frame>
    <description>Percentage of participants with a HIV-1 RNA &lt; 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA &lt; 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to [&gt;=] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA Less Than 20 and 200 Copies Per mL at Week 48 Defined by FDA Snapshot Approach</measure>
    <time_frame>At Week 48</time_frame>
    <description>Percentage of participants with HIV-1 RNA &lt; 20/200 copies per mL using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA &lt; 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA &gt;= 20/50/200 copies per mL at Week 48 ), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 20, 50, and 200 Copies Per mL at Week 48 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm</measure>
    <time_frame>At Week 48</time_frame>
    <description>Percentage of participants with HIV-1 RNA less than 20, 50, and 200 copies per mL at Week 48 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA &lt; 50 copies per mL; confirmed HIV-1 RNA &gt;= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in log10 HIV-1 RNA Levels at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in log10 HIV-1 RNA levels were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antiretroviral (ARV) Resistance Through Week 48</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Number of participants with DRV, FTC, TDF/TAF resistance were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in serum creatinine at Week 48 was reported. Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) &gt;= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): &lt;15 mL/min indicate very severe or end stage kidney failure. The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m^2) = 144 x (Scr/0.7)^-0.329 x 0.993^age (Scr =&lt; 0.7 mg/dL) and eGFRcr mL/min/1.73m^2 = 144 x (Scr/0.7)^-1.209 x 0.993^age (Scr &gt;0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m^2 = 141 x (Scr/0.9)^-0.411 x 0.993^age (Scr =&lt;0.9 mg/dL) and eGFRcr mL/min/1.73m^2 = 141 x (Scr/0.9)^-1.209 x 0.993^age (Scr &gt;0.9 mg/dL) for male participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in eGFRcr by (cockcroft-gault formula) at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl [mL/min] = (140 - A) * W / (72 * C) * R. Where A is age at sample date [years], W is body weight at specific visit (kilogram [kg]), C is the serum concentration of creatinine [mg/dL], R = 1 if the participant is male and = 0.85 if female.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) &gt;= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): &lt;15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m^2 = 133 x (Scyst/0,8)^-0.499 x 0.996^age [x 0.932 if female] (Scyst =&lt;0.8 mg/L) and eGFRcr mL/min/1.73m^2 = 133 x (Scyst/0,8)^-1.328 x 0.996^age [x 0.932 if male] (Scyst &gt;0.8 mg/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in UPCR at Week 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in UACR at Week 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in URBPCR at Week 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in UB2MGCR at Week 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Percent change from baseline in FEPO4 at Week 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir</measure>
    <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
    <description>The AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose (Trough) Plasma Concentration (C0h) of Darunavir</measure>
    <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
    <description>C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide</measure>
    <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
    <description>The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide</measure>
    <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
    <description>C0-2h is defined as as the plasma concentrations 2 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot; of change. Percent change from baseline in hip and spine BMD was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BMD T-score of Hip and Spine</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score &gt;= -1, osteopenia by a T-score &gt;= -2.5 to &lt;-1.0, and osteoporosis by a T-score &lt;-2.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase (ALP) Levels at Week 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in ALP at Week 24 and 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Week 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in serum P1NP at Week 24 and 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Week 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in serum CTX at Week 24 and 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of Parathyroid Hormone (PTH) at Week 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in PTH at Week 24 and 48 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48</measure>
    <time_frame>Baseline, Weeks 24 and 48</time_frame>
    <description>Change from baseline in 25-OH Vitamin D at Week 24 and 48 were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">725</enrollment>
  <condition>Immunodeficiency Virus Type 1, Human</condition>
  <arm_group>
    <arm_group_label>Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC</intervention_name>
    <description>A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.</description>
    <arm_group_label>Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV/COBI FDC</intervention_name>
    <description>A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.</description>
    <arm_group_label>DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF FDC</intervention_name>
    <description>A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.</description>
    <arm_group_label>DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D/C/F/TAF FDC - Matching Placebo</intervention_name>
    <description>Matching placebo of D/C/F/TAF FDC will be administered once daily.</description>
    <arm_group_label>DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF FDC Matching Placebo</intervention_name>
    <description>Matching placebo of FTC/TDF FDC will be administered once daily.</description>
    <arm_group_label>Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV/COBI FDC Matching Placebo</intervention_name>
    <description>Matching placebo of DRV/COBI FDC will be administered once daily.</description>
    <arm_group_label>Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV
             including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of any
             approved or experimental anti- human immunodeficiency virus (anti-HIV) drug for any
             length of time

          -  Screening plasma HIV-1 ribonucleic acid (RNA) level greater than or equal to &gt;=1,000
             copies per milliliter (copies/mL)

          -  Cluster of Differentiation 4+ (CD4+) cell count &gt;50 cells/microliter (cells/mcL)

          -  Screening HIV-1 genotype report must show full sensitivity to DRV, TDF and FTC

          -  Screening eGFRcreatinine &gt;=70 mL/min according to the Cockcroft-Gault formula for
             creatinine clearance

        Exclusion Criteria:

          -  Subject has been diagnosed with a new acquired immunodeficiency syndrome
             (AIDS)-defining condition within the 30 days prior to screening

          -  Subject has proven or suspected acute hepatitis within 30 days prior to screening

          -  Subject is hepatitis C or hepatitis B positive

          -  Subject has a history of cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg im Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorzow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orel</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tolyatti</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <results_first_submitted>August 15, 2018</results_first_submitted>
  <results_first_submitted_qc>August 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <disposition_first_submitted>March 2, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 5, 2018</disposition_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunodeficiency Virus Type 1, Human</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Cobicistat</keyword>
  <keyword>Tenofovir Alafenamide</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>Tenofovir Disoproxil Fumarate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02431247/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02431247/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Results are reported through Week 48 (primary analysis). Complete data through final analysis (through Week 96 and follow-up) will be reported within 1 year of end of trial date when final data based on study completion date will be available.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>D/C/F/TAF+ FTC/TDF (Test)</title>
          <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
        </group>
        <group group_id="P2">
          <title>DRV/COBI+ FTC/TDF (Control)</title>
          <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="362"/>
                <participants group_id="P2" count="363"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="339"/>
                <participants group_id="P2" count="336"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>D/C/F/TAF+ FTC/TDF (Test)</title>
          <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
        </group>
        <group group_id="B2">
          <title>DRV/COBI+ FTC/TDF (Control)</title>
          <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="362"/>
            <count group_id="B2" value="363"/>
            <count group_id="B3" value="725"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="10.17"/>
                    <measurement group_id="B2" value="35.1" spread="9.99"/>
                    <measurement group_id="B3" value="35.3" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="626"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (&lt;) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach</title>
        <description>Percentage of participants with a HIV-1 RNA &lt; 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA &lt; 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to [&gt;=] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.</description>
        <time_frame>At Week 48</time_frame>
        <population>The intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (&lt;) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach</title>
          <description>Percentage of participants with a HIV-1 RNA &lt; 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA &lt; 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to [&gt;=] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.</description>
          <population>The intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="88.1" upper_limit="94.1"/>
                    <measurement group_id="O2" value="88.4" lower_limit="84.7" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>One-sided p-value for non-inferiority of Test versus Control arm. The non-inferiority margin is 10%.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Difference in percentage</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA Less Than 20 and 200 Copies Per mL at Week 48 Defined by FDA Snapshot Approach</title>
        <description>Percentage of participants with HIV-1 RNA &lt; 20/200 copies per mL using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA &lt; 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA &gt;= 20/50/200 copies per mL at Week 48 ), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.</description>
        <time_frame>At Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA Less Than 20 and 200 Copies Per mL at Week 48 Defined by FDA Snapshot Approach</title>
          <description>Percentage of participants with HIV-1 RNA &lt; 20/200 copies per mL using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA &lt; 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA &gt;= 20/50/200 copies per mL at Week 48 ), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Less than 20 Copies per mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="78.3" upper_limit="86.4"/>
                    <measurement group_id="O2" value="79.3" lower_limit="74.8" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than 200 Copies per mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="89.7" upper_limit="95.3"/>
                    <measurement group_id="O2" value="90.6" lower_limit="87.2" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 20, 50, and 200 Copies Per mL at Week 48 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm</title>
        <description>Percentage of participants with HIV-1 RNA less than 20, 50, and 200 copies per mL at Week 48 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA &lt; 50 copies per mL; confirmed HIV-1 RNA &gt;= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.</description>
        <time_frame>At Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 20, 50, and 200 Copies Per mL at Week 48 Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm</title>
          <description>Percentage of participants with HIV-1 RNA less than 20, 50, and 200 copies per mL at Week 48 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA &lt; 50 copies per mL; confirmed HIV-1 RNA &gt;= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Less than 20 Copies per mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="78.3" upper_limit="86.4"/>
                    <measurement group_id="O2" value="79.9" lower_limit="75.4" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than 50 Copies per mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" lower_limit="87.8" upper_limit="93.9"/>
                    <measurement group_id="O2" value="88.7" lower_limit="85.0" upper_limit="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than 200 Copies per mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="90.0" upper_limit="95.5"/>
                    <measurement group_id="O2" value="91.7" lower_limit="88.4" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in log10 HIV-1 RNA Levels at Week 48</title>
        <description>Change from baseline in log10 HIV-1 RNA levels were reported.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all participants who were randomized and received at least one dose of study treatment in study. Based on not completed (NC) equal to (=) failure (F) analysis with values after discontinuation imputed with the baseline value. Other (intermittent) missing values are imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in log10 HIV-1 RNA Levels at Week 48</title>
          <description>Change from baseline in log10 HIV-1 RNA levels were reported.</description>
          <population>The ITT analysis set included all participants who were randomized and received at least one dose of study treatment in study. Based on not completed (NC) equal to (=) failure (F) analysis with values after discontinuation imputed with the baseline value. Other (intermittent) missing values are imputed using last observation carried forward (LOCF).</population>
          <units>log10 HIV-1 RNA copies per mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.044"/>
                    <measurement group_id="O2" value="-2.91" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.437</p_value>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.171</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48</title>
        <description>The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Based on NC = F analysis with values after discontinuation imputed with the baseline value. Other (intermittent) missing values are imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation-4 (CD4+) Cell Count at Week 48</title>
          <description>The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Based on NC = F analysis with values after discontinuation imputed with the baseline value. Other (intermittent) missing values are imputed using LOCF.</population>
          <units>Cells per millimeter cube (cells/mm^3)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.49" spread="10.472"/>
                    <measurement group_id="O2" value="172.01" spread="10.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.213</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>18.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.808</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.595</ci_lower_limit>
            <ci_upper_limit>47.550</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Antiretroviral (ARV) Resistance Through Week 48</title>
        <description>Number of participants with DRV, FTC, TDF/TAF resistance were reported.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antiretroviral (ARV) Resistance Through Week 48</title>
          <description>Number of participants with DRV, FTC, TDF/TAF resistance were reported.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Week 48</title>
        <description>Change from baseline in serum creatinine at Week 48 was reported. Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Week 48</title>
          <description>Change from baseline in serum creatinine at Week 48 was reported. Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.006"/>
                    <measurement group_id="O2" value="0.09" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.008</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48</title>
        <description>Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) &gt;= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): &lt;15 mL/min indicate very severe or end stage kidney failure. The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m^2) = 144 x (Scr/0.7)^-0.329 x 0.993^age (Scr =&lt; 0.7 mg/dL) and eGFRcr mL/min/1.73m^2 = 144 x (Scr/0.7)^-1.209 x 0.993^age (Scr &gt;0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m^2 = 141 x (Scr/0.9)^-0.411 x 0.993^age (Scr =&lt;0.9 mg/dL) and eGFRcr mL/min/1.73m^2 = 141 x (Scr/0.9)^-1.209 x 0.993^age (Scr &gt;0.9 mg/dL) for male participants.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine (eGFRcr) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula at Week 48</title>
          <description>Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) &gt;= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): &lt;15 mL/min indicate very severe or end stage kidney failure. The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m^2) = 144 x (Scr/0.7)^-0.329 x 0.993^age (Scr =&lt; 0.7 mg/dL) and eGFRcr mL/min/1.73m^2 = 144 x (Scr/0.7)^-1.209 x 0.993^age (Scr &gt;0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m^2 = 141 x (Scr/0.9)^-0.411 x 0.993^age (Scr =&lt;0.9 mg/dL) and eGFRcr mL/min/1.73m^2 = 141 x (Scr/0.9)^-1.209 x 0.993^age (Scr &gt;0.9 mg/dL) for male participants.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.04" spread="0.551"/>
                    <measurement group_id="O2" value="-9.16" spread="0.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>3.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.786</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>4.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48</title>
        <description>Change from baseline in eGFRcr by (cockcroft-gault formula) at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl [mL/min] = (140 - A) * W / (72 * C) * R. Where A is age at sample date [years], W is body weight at specific visit (kilogram [kg]), C is the serum concentration of creatinine [mg/dL], R = 1 if the participant is male and = 0.85 if female.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Creatinine by (Cockcroft-Gault Formula) at Week 48</title>
          <description>Change from baseline in eGFRcr by (cockcroft-gault formula) at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl [mL/min] = (140 - A) * W / (72 * C) * R. Where A is age at sample date [years], W is body weight at specific visit (kilogram [kg]), C is the serum concentration of creatinine [mg/dL], R = 1 if the participant is male and = 0.85 if female.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>milliliter per minute (mL/min)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.16" spread="0.790"/>
                    <measurement group_id="O2" value="-11.20" spread="0.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>6.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.126</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.83</ci_lower_limit>
            <ci_upper_limit>8.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48</title>
        <description>Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) &gt;= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): &lt;15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m^2 = 133 x (Scyst/0,8)^-0.499 x 0.996^age [x 0.932 if female] (Scyst =&lt;0.8 mg/L) and eGFRcr mL/min/1.73m^2 = 133 x (Scyst/0,8)^-1.328 x 0.996^age [x 0.932 if male] (Scyst &gt;0.8 mg/L).</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate Based on Serum Cystatin C (eGFRcyst) by CKD-EPI Formula at Week 48</title>
          <description>Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) &gt;= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): &lt;15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m^2 = 133 x (Scyst/0,8)^-0.499 x 0.996^age [x 0.932 if female] (Scyst =&lt;0.8 mg/L) and eGFRcr mL/min/1.73m^2 = 133 x (Scyst/0,8)^-1.328 x 0.996^age [x 0.932 if male] (Scyst &gt;0.8 mg/L).</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" spread="0.525"/>
                    <measurement group_id="O2" value="2.92" spread="0.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>2.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.747</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>3.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events</title>
        <description>AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Premature Discontinuations Due to Adverse Events</title>
          <description>AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48</title>
        <description>Change from baseline in UPCR at Week 48 were reported.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48</title>
          <description>Change from baseline in UPCR at Week 48 were reported.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>milligram per gram (mg/g)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.72" lower_limit="-748.1" upper_limit="254.2"/>
                    <measurement group_id="O2" value="-10.53" lower_limit="-903.0" upper_limit="1546.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.033</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48</title>
        <description>Change from baseline in UACR at Week 48 were reported.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Albumin to Creatinine Ratio (UACR) at Week 48</title>
          <description>Change from baseline in UACR at Week 48 were reported.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>mg/g</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" lower_limit="-226.5" upper_limit="143.8"/>
                    <measurement group_id="O2" value="-0.15" lower_limit="-640.4" upper_limit="969.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.003</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48</title>
        <description>Change from baseline in URBPCR at Week 48 were reported.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Retinol Binding Protein To Creatinine Ratio (URBPCR) at Week 48</title>
          <description>Change from baseline in URBPCR at Week 48 were reported.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>microgram per gram (mcg/g)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="-1555.7" upper_limit="5183.8"/>
                    <measurement group_id="O2" value="35.02" lower_limit="-700.7" upper_limit="30350.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48</title>
        <description>Change from baseline in UB2MGCR at Week 48 were reported.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Beta-2 Microglobulin to Creatinine Ratio (UB2MGCR) at Week 48</title>
          <description>Change from baseline in UB2MGCR at Week 48 were reported.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>mcg/g</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.42" lower_limit="-11818.6" upper_limit="3452.0"/>
                    <measurement group_id="O2" value="18.36" lower_limit="-2440.5" upper_limit="90832.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48</title>
        <description>Percent change from baseline in FEPO4 at Week 48 were reported.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine Fractional Excretion of Phosphate (FEPO4) at Week 48</title>
          <description>Percent change from baseline in FEPO4 at Week 48 were reported.</description>
          <population>The ITT analysis set included all the participants who were randomized and received at least one dose of study treatment in the study. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" lower_limit="-87.3" upper_limit="1756.6"/>
                    <measurement group_id="O2" value="22.55" lower_limit="-90.1" upper_limit="1720.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.147</p_value>
            <method>Wilcoxon rank sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir</title>
        <description>The AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post dose.</description>
        <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
        <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of DRV was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 800 mg [D/C/F/TAF+ FTC/TDF (Test)]</title>
            <description>Participants received DRV 800 mg along with COBI 150 mg, FTC 200 mg, TAF 10 mg as a (D/C/F/TAF) FDC oral tablet once daily along with DRV/COBI FDC-matching placebo and FTC/TDF FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h) of Darunavir</title>
          <description>The AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post dose.</description>
          <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of DRV was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87909.3282" spread="20232.09905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predose (Trough) Plasma Concentration (C0h) of Darunavir</title>
        <description>C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.</description>
        <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
        <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of DRV was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 800 mg [D/C/F/TAF+ FTC/TDF (Test)]</title>
            <description>Participants received DRV 800 mg along with COBI 150 mg, FTC 200 mg, TAF 10 mg as a (D/C/F/TAF) FDC oral tablet once daily along with DRV/COBI FDC-matching placebo and FTC/TDF FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Predose (Trough) Plasma Concentration (C0h) of Darunavir</title>
          <description>C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.</description>
          <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of DRV was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1898.9100" spread="758.83837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide</title>
        <description>The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.</description>
        <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
        <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of TAF was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Alafenamide 10 mg [D/C/F/TAF+ FTC/TDF (Test)]</title>
            <description>Participants received TAF 10 mg along with DRV 800 mg, COBI 150 mg, FTC 200 mg as a (D/C/F/TAF) FDC oral tablet once daily along with DRV/COBI FDC-matching placebo and FTC/TDF FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve Across the Dosing Interval (AUCtau) of Tenofovir Alafenamide</title>
          <description>The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.</description>
          <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of TAF was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.3117" spread="40.87742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide</title>
        <description>C0-2h is defined as as the plasma concentrations 2 hours after dosing.</description>
        <time_frame>30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)</time_frame>
        <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of TAF was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Alafenamide 10 mg [D/C/F/TAF+ FTC/TDF (Test)]</title>
            <description>Participants received TAF 10 mg along with DRV 800 mg, COBI 150 mg, FTC 200 mg as a (D/C/F/TAF) FDC oral tablet once daily along with DRV/COBI FDC-matching placebo and FTC/TDF FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations 2 Hours After Dosing (C0-2h) of Tenofovir Alafenamide</title>
          <description>C0-2h is defined as as the plasma concentrations 2 hours after dosing.</description>
          <population>Pharmacokinetic(PK) analysis set: all participants who were randomized, received at least 1 dose of study drug and plasma concentration data for analytes of interest were available. PK data of TAF was analyzed only for test arm as per planned analyses. 'N'(number of participants analyzed): number of participants evaluable for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9785" spread="11.86104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)</title>
        <description>The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot; of change. Percent change from baseline in hip and spine BMD was assessed.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>Bone investigation substudy (BIS) analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hip and Spine Bone Mineral Density (BMD)</title>
          <description>The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are &quot;best values&quot; and negative values are &quot;worst values&quot; of change. Percent change from baseline in hip and spine BMD was assessed.</description>
          <population>Bone investigation substudy (BIS) analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hip region BMD (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.248"/>
                    <measurement group_id="O2" value="-1.66" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine region BMD (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.285"/>
                    <measurement group_id="O2" value="-3.43" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip region BMD (Week 48)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.322"/>
                    <measurement group_id="O2" value="-2.69" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine region BMD (Week 48)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.402"/>
                    <measurement group_id="O2" value="-2.38" spread="0.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hip region BMD (Week 24)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>1.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.368</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.227</ci_lower_limit>
            <ci_upper_limit>2.678</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hip region BMD (Week 48)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>2.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.470</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.934</ci_lower_limit>
            <ci_upper_limit>3.791</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spine region BMD (Week 24)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>2.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.421</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.259</ci_lower_limit>
            <ci_upper_limit>2.919</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spine region BMD (Week 48)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.004</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>1.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.588</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>2.858</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BMD T-score of Hip and Spine</title>
        <description>BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score &gt;= -1, osteopenia by a T-score &gt;= -2.5 to &lt;-1.0, and osteoporosis by a T-score &lt;-2.5.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BMD T-score of Hip and Spine</title>
          <description>BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score &gt;= -1, osteopenia by a T-score &gt;= -2.5 to &lt;-1.0, and osteoporosis by a T-score &lt;-2.5.</description>
          <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
          <units>BMD T-score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hip region BMD T-score (Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.0180"/>
                    <measurement group_id="O2" value="-0.109" spread="0.0157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine region BMD T-score( Week 24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.121" spread="0.0259"/>
                    <measurement group_id="O2" value="-0.322" spread="0.0307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip region BMD T-score (Week 48)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.0213"/>
                    <measurement group_id="O2" value="-0.177" spread="0.0225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spine region BMD T-score( Week 48)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" spread="0.0390"/>
                    <measurement group_id="O2" value="-0.225" spread="0.0386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alkaline Phosphatase (ALP) Levels at Week 24 and 48</title>
        <description>Change from baseline in ALP at Week 24 and 48 were reported.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase (ALP) Levels at Week 24 and 48</title>
          <description>Change from baseline in ALP at Week 24 and 48 were reported.</description>
          <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
          <units>Units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.17"/>
                    <measurement group_id="O2" value="12.0" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.29"/>
                    <measurement group_id="O2" value="15.1" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Week 24 and 48</title>
        <description>Change from baseline in serum P1NP at Week 24 and 48 were reported.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of Serum Procollagen 1 N-Terminal Propeptide (P1NP) at Week 24 and 48</title>
          <description>Change from baseline in serum P1NP at Week 24 and 48 were reported.</description>
          <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
          <units>microgram per liter (mcg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.892" spread="1.3754"/>
                    <measurement group_id="O2" value="24.679" spread="2.0956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.065" spread="1.6428"/>
                    <measurement group_id="O2" value="24.251" spread="2.6337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Week 24 and 48</title>
        <description>Change from baseline in serum CTX at Week 24 and 48 were reported.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of Serum Collagen Type 1 Beta Carboxy Telopeptide (CTX) at Week 24 and 48</title>
          <description>Change from baseline in serum CTX at Week 24 and 48 were reported.</description>
          <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.0165"/>
                    <measurement group_id="O2" value="0.283" spread="0.0251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="0.0174"/>
                    <measurement group_id="O2" value="0.226" spread="0.0234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of Parathyroid Hormone (PTH) at Week 24 and 48</title>
        <description>Change from baseline in PTH at Week 24 and 48 were reported.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of Parathyroid Hormone (PTH) at Week 24 and 48</title>
          <description>Change from baseline in PTH at Week 24 and 48 were reported.</description>
          <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
          <units>Picomol per liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="0.2171"/>
                    <measurement group_id="O2" value="0.777" spread="0.2401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.2232"/>
                    <measurement group_id="O2" value="0.633" spread="0.2155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48</title>
        <description>Change from baseline in 25-OH Vitamin D at Week 24 and 48 were reported.</description>
        <time_frame>Baseline, Weeks 24 and 48</time_frame>
        <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>D/C/F/TAF+ FTC/TDF (Test)</title>
            <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
          </group>
          <group group_id="O2">
            <title>DRV/COBI+ FTC/TDF (Control)</title>
            <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Levels of 25-Hydroxyvitamin D (25-OH Vitamin D), at Week 24 and 48</title>
          <description>Change from baseline in 25-OH Vitamin D at Week 24 and 48 were reported.</description>
          <population>BIS analysis set included all participants who were randomized, received at least 1 dose of study drug in study and had at least one post-baseline value for either biomarker/BMD data. Here 'n' (number analyzed) signifies number of participants analyzed at specific timepoint.</population>
          <units>nanomol per liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="2.76"/>
                    <measurement group_id="O2" value="22.1" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="2.84"/>
                    <measurement group_id="O2" value="28.3" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 48 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>D/C/F/TAF+ FTC/TDF (Test)</title>
          <description>Participants received a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching placebo and FTC/tenofovir disoproxil fumarate (TDF) FDC-matching placebo tablets once daily up to Week 48.</description>
        </group>
        <group group_id="E2">
          <title>DRV/COBI+ FTC/TDF (Control)</title>
          <description>Participants received DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bone marrow oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis sclerosing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="311" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="304" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Type V hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ear canal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Retinal scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dental discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lip disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Salivary gland pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tongue dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anal chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anorectal infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bacterial food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Balanoposthitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ecthyma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Eyelid infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Genital herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Genitourinary chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lice infestation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Mycoplasma genitalium infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oral hairy leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oropharyngeal gonococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Overgrowth bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pharyngeal chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Proctitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Proctitis chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Proctitis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Schistosomiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Urethritis chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Urethritis gonococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Periorbital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anal pap smear abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin urine abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin urine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood 1,25-dihydroxycholecalciferol decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood 25-hydroxycholecalciferol decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood parathyroid hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bone density increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cystatin C abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Human papilloma virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lipids increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lymphocyte morphology abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Axillary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Jaw cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Spinal cord neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dizziness exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Borderline personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nicotine dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tobacco abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nephroptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Urethral discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Erection increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Galactorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Genital burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Genital lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Penile blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Perineal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Penile ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Precancerous skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash morbilliform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin maceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Solar dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Dental prosthesis user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior director, Medical leader</name_or_title>
      <organization>Janssen Sciences Ireland</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

